Biocardia letter to shareholders

Sunnyvale, calif., dec. 22, 2022 (globe newswire) -- biocardia, inc. (nasdaq: bcda), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders:
BCDA Ratings Summary
BCDA Quant Ranking